Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Analyst picks & changes

Argus Pharmaceuticals Inc.

(ARGS)

Robert Faulkner of S.G. Warburg said the merger between ARGS, Triplex Pharmaceutical Corp. and

Read the full 185 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE